SecurityUBP / Urstadt Biddle Properties, Inc.
President and CEOBIDDLE WILLING L
IndustryReal Estate Investment Trusts
Institutional Owners0
Common Shares Outstanding229,813,577 shares (as of 2018-07-31)
Related UBP.PRH / Urstadt Biddle Properties Inc.
UBP.PRF / Urstadt Biddle Properties, Inc.
UBA / Urstadt Biddle Properties, Inc.
UBP.PRG / Urstadt Biddle Properties, Inc.

Institutional Stock Ownership and Shareholders

Urstadt Biddle Properties, Inc. (NYSE:UBP) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
Urstadt Biddle Properties, Inc. (NYSE:UBP) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Important Note!
Note: We do not currently have a CUSIP on file for this security. That means we are unable to search institutional fund filings (13F's) for this company, which means there may be institutional holders that we are unaware of. If you know the CUSIP or would like us to research and update this security, please let us know by leaving a message in the Welcome Group.
File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Urstadt Biddle Properties (UBA) Surpasses Q3 FFO and Revenue Estimates

2018-09-07 zacks
Urstadt Biddle Properties (UBA - Free Report) came out with quarterly funds from operations (FFO) of $0.35 per share, beating the Zacks Consensus Estimate of $0.33 per share. This compares to FFO of $0.37 per share a year ago. These figures are adjusted for non-recurring items.

Urstadt Biddle Properties: Hold For The Coming 2019 Catalyst

2018-08-23 seekingalpha
As a fairly obscure regional shopping center Real Estate Investment Trust (REIT), Urstadt Biddle Properties is little known to most investors. (5-0)

Urstadt Biddle Properties Sees Hammer Chart Pattern: Time to Buy?

2018-08-08 zacks
Urstadt Biddle Properties Inc. (UBA - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because UBA recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom. (1-0)

Is Urstadt Biddle Properties (UBA) a Great Dividend Play?

2018-07-26 zacks
All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.

A Health Care REIT That Willy Wonka Would Love

2018-07-23 seekingalpha
While some pundits believe that skilled nursing rents will continue to decline, the bulls (like me) argue that the supply and demand fundamentals will drive returns.

Has Urstadt Biddle Properties (UBA) Outpaced Other Finance Stocks This Year?

2018-07-12 zacks
For those looking to find strong Finance stocks, it is prudent to search for companies in the group that are outperforming their peers. Urstadt Biddle Properties (UBA - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of UBA and the rest of the Finance group's stocks.

UBA or BFS: Which Is the Better Value Stock Right Now?

2018-07-12 zacks
Investors looking for stocks in the REIT and Equity Trust - Retail sector might want to consider either Urstadt Biddle Properties (UBA - Free Report) or Saul Centers (BFS - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.

Moving Average Crossover Alert: Urstadt Biddle Properties (UBA)

2018-06-27 zacks
Urstadt Biddle Properties Inc. (UBA - Free Report) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for UBA broke out above the 200 Day Simple Moving Average, suggesting a short-term bullish trend. (3-0)

Hey Diddle Diddle, I'm Upgrading Urstadt Biddle

2018-06-11 seekingalpha
Back in March I wrote an article on Urstadt Biddle (UBA) titled, Urstadt Biddle Could Become Another 'Cinderella Story, in which I explained that after “reviewing the recent earnings results, UBA has earned a ticket to the Sweet Sixteen and I have upgraded shares to a STRONG BUY.” (4-0)

106 Dividend Achievers Yield 2.4%-10.4% For June

2018-06-06 seekingalpha
Dividend Achiever stocks are distinguished by 10 or more straight years of higher dividends. Some 266 Achiever equities are balanced by sector and capitalization. (39-1)